文献速递胃肠动力与功能性疾病

基于CYP2D6基因型指导的诺替林个体化治疗功能性消化不良的多中心随机对照试验

Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-01-29

主要终点(治疗最后10周中至少50%的周数症状较基线下降≥30%)在诺替林组与安慰剂组无显著差异(45% vs 58%;OR 0.574;95%CI 0.211-1.560;诺替林血药浓度在应答者中显著高于非应答者,且患者对接受诺替林的信念与更高应答率相关(77% vs 36%;OR 11.439;95%CI 2.138-61.201;

要点

  • 基于CYP2D6基因型预选的FD患者中,诺替林12周治疗未显著优于安慰剂。

核心结论

  • 在基于CYP2D6基因型预选的功能性消化不良患者中,诺替林递减低剂量方案在减少FD症状方面不优于安慰剂,但不能排除诺替林的生物学效应,且与患者信念相关的效应似乎更强。

研究设计与样本

  • 根据CYP2D6基因型预选后随机分配至诺替林组(第1-2周10 mg,第3-4周25 mg,第5-12周50 mg)或安慰剂组,治疗12周。
  • 主要终点为治疗期最后10周中至少50%的周数FD症状较基线下降≥30%的临床应答。

主要发现

  • 诺替林组与安慰剂组不良事件无显著差异。

临床怎么用

  • 对于FD患者,不推荐常规基于CYP2D6基因型预选后使用诺替林递减低剂量方案以改善症状,因该策略未显示优于安慰剂。
  • 诺替林血药浓度与应答相关,提示若使用诺替林可考虑监测血药浓度,但需进一步研究验证。
  • 患者对治疗的信念可能显著影响FD治疗应答,临床中应关注安慰剂效应和医患沟通。

局限性

  • 研究基于CYP2D6基因型预选,结果可能不适用于未预选人群。
  • 不能排除诺替林的生物学效应,因血药浓度与应答相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Low-dose tricyclic antidepressants may be effective for patients with functional dyspepsia (FD), although high-quality randomized controlled trials (RCTs) are limited. We aimed to investigate the efficacy of nortriptyline in an escalating low-dose regimen vs placebo in participants with FD following a genotype-guided pre-selection based on cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for nortriptyline metabolism. METHODS: We conducted a multicenter, RCT of patients with FD in primary, secondary, and tertiary care. Sixty-nine participants were randomly assigned to nortriptyline (weeks 1-2: 10 mg; weeks 3-4: 25 mg; weeks 5-12: 50 mg) vs placebo for a 12-week treatment. The primary outcome was clinical response based on a decrease in FD symptoms of at least 30% compared with baseline, in 50% of the last 10 weeks of the treatment period. RESULTS: The primary outcome showed no significant difference in response for nortriptyline compared with placebo (45% vs 58%; odds ratio [OR], 0.574; 95% confidence interval [CI], 0.211-1.560; P = .276). There was no significant difference in adverse events between the nortriptyline and placebo group. Nortriptyline plasma levels were significantly higher in responders compared with non-responders (13.0 μg/L; interquartile range [IQR], 12.0-16.0 vs 9.0 μg/L; IQR, 8.0-10.5; P = .003). The belief to have received nortriptyline showed a higher response rate than the belief to have received placebo (77% vs 36%; OR, 11.439; 95% CI, 2.138-61.201; P = .004). CONCLUSIONS: Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. However, effects related to participants' belief appeared to be stronger. CLINICALTRIALS: gov, Number, NCT03652571.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bosch DHCA, Beckers AB, Snijkers JTW, et al. Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2026. PMID: 41616902. doi:10.1016/j.cgh.2026.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。